TABLE 4.
Clinical characteristics and outcomes of patients with CRAB infections who died and who did not within 30 days from infectiona
| Variable | 30-day mortality (N = 59) | Survivors (N = 65) | p b |
|---|---|---|---|
| Age, median, IQRs | 71 (65–77) | 59 (42–73) | <0.001 |
| Male sex | 49 (83.1%) | 43 (66.2%) | 0.032 |
| Comorbidities | |||
| Diabetes mellitus | 12 (20.3%) | 11 (16.9%) | 0.625 |
| Cardiovasculardisease | 42 (71.2%) | 31 (47.7%) | 0.008 |
| COPD | 12 (20.3%) | 5 (7.7%) | 0.041 |
| Chronicrenaldisease | 7 (11.9%) | 2 (3.1%) | 0.060 |
| Chronicliverdisease | 4 (6.8%) | 1 (1.5%) | 0.138 |
| Solid cancer | 3 (5.1%) | 5 (7.7%) | 0.555 |
| COVID-19 | 31 (52.5%) | 17 (26.2%) | 0.003 |
| Ward of hospitalization | |||
| Medicalwards | 6 (10.2%) | 6 (9.2%) | 0.860 |
| Surgery | 0 | 1 (1.5%) | 1.0 |
| ICU | 53 (89.8%) | 58 (89.2%) | 0.913 |
| Type of infections | |||
| BSI | 37 (62.7%) | 42 (64.6%) | 0.826 |
| VAP | 20 (33.9%) | 15 (23.1%) | 0.181 |
| Other | 2 (3.4%) | 8 (12.3%) | 0.069 |
| Charlson Comorbidity Index, median, IQRs | 4 (3–5) | 2 (1–5) | 0.002 |
| SOFA score, median, IQRs | 10 (9–11) | 6 (2.25–9) | <0.001 |
| APACHE II score, median, IQRs | 21 (16–25) | 12 (7–20) | <0.001 |
| Invasive mechanical ventilation | 41 (71.9%) | 29 (44.6%) | 0.002 |
| Intravascular device | 59 (100%) | 65 (100%) | |
| Septic shock | 50 (84.7%) | 25 (38.5%) | <0.001 |
| AKI at time of sepsis | 24 (40.7%) | 7 (10.8%) | <0.001 |
| Parenteral nutrition | 19 (32.2%) | 20 (30.8%) | 0.864 |
| ECMO at time of sepsis | 5(8.5%) | 4(6.2%) | 0.619 |
| CVVH at time of sepsis | 9 (15.5%) | 5 (7.7%) | 0.173 |
| Source control | 20 (33.9%) | 29 (44.6%) | 0.223 |
| Polymicrobial infections | 16 (27.1%) | 14 (21.5%) | 0.469 |
| Duration of targeted antibiotic therapy | 8 (5–12) | 8 (12–14) | 0.03 |
| Cefiderocol-based regimen | 16 (27.1%) | 31 (47.7%) | 0.018 |
| Cefiderocol monotherapy | 1 (1.7%) | 14 (21.5%) | 0.001 |
| Microbiological failurec | 0/59 | 13/61 (21.3%) | <0.001 |
a
AKI: acute kidney injury; BSI: bloodstream infections; CFDC: cefiderocol; ECMO: extra corporeal membrane oxygenation; CVVH: continuous venovenous hemofiltration; ICU: intensive care units; IQRs: interquartile ranges; VAP: ventilator-associated pneumonia.
b
Boldface italic entries are statistically significant (P < 0.05).
c
Microbiological failure available on 120/124 patients who had follow-up cultures available.